Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug Angladewe Tablets (brand name: Anruiwei) has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations for 2025 [1] Group 1: Company Developments - The company announced that its core products, including Lai Ru Te Wei Tablets, Compound Thrombus Tong Capsules, Cerebral Thrombus Tong Capsules, Sucralfate Oral Suspension, Carboxymethyl Starch Oral Solution, and Nitazoxanide Eye Drops, have also been included in the National Medical Insurance Directory [1]

2025 年 12 月 7 日，根据国家医保局、人力资源社会保障部发布的《关于印 发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新 药品目录>（2025 年）的通知》（医保发〔2025〕33 号），广东众生药业股份有 限公司（以下简称"公司"）一类创新药物昂拉地韦片（商品名：安睿威®）通 过国家医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药品目 录（2025 年）》（以下简称"《国家医保目录》"）。同时，公司核心产品来 瑞特韦片、复方血栓通胶囊、脑栓通胶囊、硫糖铝口服混悬液、羧甲司坦口服溶 液、盐酸氮䓬斯汀滴眼液等继续入选本次《国家医保目录》。 昂拉地韦片（商品名：安睿威®）是全球首款靶向甲型流感病毒 RNA 聚合 酶 PB2 亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，具有快速、 强效、低耐药等特点，能够快速缓解全身流感症状、强效抗击流感病毒，兼具低 耐药性，于 2025 年 5 月获国家药监局批准上市。昂拉地韦片是公司呼吸管线的 创新药重要产品，本次成功纳入《国家医保目录》乙类范围，有望惠及更多患者， 为患者提供经济、安全、可及的用药选择。 昂拉地韦片入选《 ...

根据国家医保局公布的2025年《国家基本医疗保险、生育保险和工伤保险药品目录》，今年有两款 新获批上市的国产抗流感病毒药物，成功进入该目录，分别是众生药业的昂拉地韦片以及青峰医药的 玛舒拉沙韦片。 编辑：小羊 ...

证券日报网讯 12月5日，众生药业在互动平台回答投资者提问时表示，昂拉地韦片作为处方药，其销 售、发放需严格遵循国家药品监管法规，需由具备资质的医疗机构根据患者具体病情开具处方后，通过 合规医疗渠道获取。公司高度重视投资者的合法利益，积极做好经营管理、产品研发等工作，不断提升 公司内在价值，通过健康的发展切实维护广大投资者利益，为股东带来更好的回报。 （文章来源：证券日报） ...

Group 1: International Medicine - International Medicine plans to raise up to approximately 1.008 billion yuan through a private placement of A-shares to no more than 35 specific investors [1] - The raised funds will be allocated to three main projects: Smart Health and Elderly Care project (total investment of about 751 million yuan, with approximately 638 million yuan from the raised funds), Phase II of the Proton Therapy Center (total investment of 99.93 million yuan, with 99.93 million yuan from the raised funds), and working capital (total investment of 270 million yuan, with 270 million yuan from the raised funds) [1] Group 2: Zhongtai Securities - Zhongtai Securities reports that the innovative drug sector remains the most important theme in the pharmaceutical industry, with recent adjustments leading to a more reasonable valuation and increased safety margins [2] - The report suggests that the innovative drug sector has entered a favorable allocation window following a correction, and highlights structural rotation opportunities within the sector [2] Group 3: Zhongsheng Pharmaceutical - Zhongsheng Pharmaceutical's subsidiary has received approval for clinical trials of the innovative peptide drug RAY1225 for the treatment of Metabolic Associated Steatotic Hepatitis (MASH) [3] - The approval is significant as there are currently no approved drugs for this condition in the domestic market, indicating a clear market demand and considerable potential [3] Group 4: Tiantan Biological - Tiantan Biological's "Human Prothrombin Complex" has completed Phase III clinical trials, showing significant improvement in coagulation factor levels and bleeding symptoms in patients with Hemophilia B [4] - The positive results from the clinical trials provide a critical foundation for the product's market application, marking an important advancement in the field of blood products [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 申请的适应症：代谢相关脂肪性肝炎。 受理号：CXHL2501038、CXHL2501039、CXHL2501040、CXHL2501041、CXHL2501042 通知书编号：2025LP03262、2025LP03263、2025LP03264、2025LP03265、2025LP03266 证券代码：002317公告编号：2025-112 广东众生药业股份有限公司关于控股子公司 收到一类创新药RAY1225注射液新增适应症的药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众生睿创生物科技有限公司（以 下简称"众生睿创"）自主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝 炎"的药物临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225注射液新增适应症进行临床试验。具体情况如下： 一、《药物临床试验批准通知书》基本情况 根据《中华人民共和国药品管理法》及 ...

证券日报网讯 12月4日晚间，众生药业发布公告称，近日，公司控股子公司广东众生睿创生物科技有限 公司自主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试 验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液新增适 应症进行临床试验。 （文章来源：证券日报） ...

公告显示，RAY1225注射液是创新结构多肽药物，具有GLP-1受体和GIP受体双重激动活性，得益于优 异的药代动力学特性，具备每两周注射一次的长效药物潜力。 北京商报讯（记者 丁宁）12月4日晚间，众生药业（002317）发布公告称，公司控股子公司广东众生睿 创生物科技有限公司自主研发的一类创新多肽药物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝 炎"的药物临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225注射液新增适应症进行临床试验。 ...

Core Insights - The Hong Kong and A-share innovative drug sectors have shown significant weekly performance, with notable increases in specific stocks such as Haiwang Bio and Kangfang Biotech, indicating a positive trend in the market [2][4][5]. Market Performance - The pharmaceutical and biotechnology index rose by 1.50%, outperforming the Shanghai Composite Index by 0.10 percentage points, marking two consecutive weeks of gains [4]. - The innovative drug sector (BK1106) saw a weekly increase of 4.26%, while the Hang Seng Healthcare Index (HSCICH) rose by 3.64% and the Hong Kong innovative drug ETF (513120) increased by 4.00% [4]. Stock Highlights - Haiwang Bio experienced a remarkable weekly increase of 38.21%, while Kangfang Biotech led with a 14.86% rise [2]. - The focus on children's antiviral drugs is highlighted by the initiation of Phase III trials for the drug Anladiwei by Zhongsheng Pharmaceutical, targeting a critical market need [12][13]. IPO Developments - Lingke Pharmaceutical has filed for an IPO in Hong Kong, focusing on innovative drugs for autoimmune and inflammatory diseases, with its lead candidate LNK01001 facing intense competition from existing JAK inhibitors [6][7]. - The company reported R&D expenditures of approximately 186 million yuan, 223 million yuan, and 121 million yuan for the years 2023, 2024, and the first nine months of 2025, respectively [7]. Clinical Trials - A total of 110 clinical trial registrations were disclosed by the National Medical Products Administration, with 39 trials in Phase II or higher, indicating robust activity in drug development [8]. - The ongoing clinical trials for various drugs, including SKB500 for small cell lung cancer and Anladiwei for pediatric influenza, reflect the industry's focus on addressing unmet medical needs [14][12]. Regulatory Approvals - Four innovative drugs received approval during the week, including Yimazhi for pediatric Tourette syndrome and a radiopharmaceutical for prostate cancer detection [11]. - The approval of Anladiwei for adult treatment earlier this year and its subsequent pediatric trial initiation underscores the strategic expansion of product lines to meet market demands [13].

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]